中国临床药学杂志

参考文献

[1] LUTSEY P L, ZAKAI N A. Epidemiology and prevention of venous thromboembolism[J]. Nat Rev Cardiol, 2023, 20(4):248.

[2]朱光发.侵袭性肺真菌病诊治指南解析[J].心肺血管病杂志,2012, 31(2):137.

[3] LEUNG J M, OBEIDAT M, SADATSAFAVI M, et al. Introduction to precision medicine in COPD[J]. Eur Respir J, 2019, 53(4):1802460.

[4] JU W, ZHENG R S, ZHANG S W, et al. Cancer statistics in Chinese older people, 2022:current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea[J].Sci China Life Sci, 2023, 66(5):1079.

[5]《医养结合机构衰弱老年人多重用药安全管理中国专家共识(版)》编写组,中国老年医学学会医养结合促进委员会.医养结合机构衰弱老年人多重用药安全管理中国专家共识(2022版)[J].中国心血管杂志, 2022, 27(5):403.

[6]张晓丹,向倩,胡琨,等.药物基因组学在新药临床研究中的应用现状[J].中国临床药理学杂志, 2017, 33(23):2508.

[7] GROUP O L O E W, DURIEUX N, PASLEAU F, et al. The Oxford2011 Levels of Evidence[EB/OL].(2011-07-08)[2024-1-30].http://www.cebm.net/index.aspx?o=5653.

[8] BILLINGTON C K, PENN R B, HALL I P. β2 agonists[J].Handb Exp Pharmacol, 2017, 237:23.

[9] KATSAROU M S, KARATHANASOPOULOU A,ANDRIANOPOULOU A, et al. Beta 1, beta 2 and beta 3 adrenergic r eceptor gene polymorphisms in a southeastern European population[J]. Front Genet, 2018, 9:560.

[10] ZUURHOUT M J, VIJVERBERG S J, RAAIJMAKERS J A, et al.Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists:results of the PACMAN cohort[J]. Pharmacogenomics, 2013, 14(16):1965.

[11] BASU K, PALMER C N, TAVENDALE R, et al. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroidtreated asthmatic patients taking frequent albuterol or salmeterol[J]. J Allergy Clin Immunol, 2009, 124(6):1188.

[12] HIKINO K, KOBAYASHI S, OTA E, et al. A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol(salbutamol)therapy in patients with asthma[J]. Br J Clin Pharmacol, 2021, 87(4):1708.

[13] HU X Y, DENG S, LUO L S, et al. GLCCI1 deficiency induces glucocorticoid resistance via the competitive binding of IRF1:GRIP1 and IRF3:GRIP1 in asthma[J]. Front Med, 2021, 8:686493.

[14] HIRAI K, SHIRAI T, RACHI Y, et al. Impact of gene expression associated with glucocorticoid-induced transcript 1(GLCCI1)on severe asthma and future exacerbation[J]. Biol Pharm Bull,2019, 42(10):1746.

[15] TANTISIRA K G, LASKY-SU J, HARADA M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma[J]. N Engl J Med, 2011, 365(13):1173.

[16] RIJAVEC M,?AVBI M, LOPERT A, et al. GLCCI1 polymorphism rs37973 and response to treatment of asthm a with inhaled corticosteroids[J]. J Investig Allergol Clin Immunol, 2018,28(3):165.

[17] PARK H W, YANG M S, PARK C S, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response[J]. Allergy, 2009, 64(5):778.

[18] BOLLMEIER S G, LEE S. The emerging role of tiotropium for patients with asthma[J]. Ann Pharmacother, 2013, 47(5):704.

[19]中华人民共和国国家卫生和计划生育委员会.药物代谢酶和药物作用靶点基因检测技术指南(试行)概要[J].实用器官移植电子杂志, 2015, 3(5):257.

[20] PUSSEGODA K, ROSS C J, VISSCHER H, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children[J]. Clin Pharmacol Ther, 2013, 94(2):243.

[21] CARLETON B C, ROSS C J, PUSSEGODA K, et al. Genetic markers of cisplatin-induced hearing loss in children[J]. Clin Pharmacol Ther, 2014, 96(3):296.

[22] SIEMENS A, BROOKS B, RASSEKH S R, et al. Role of cisplatin dose intensity and TPMT variation in the development of hearing loss in children[J]. Ther Drug Monit, 2023, 45(3):345.

[23] ROSS C J, KATZOV-ECKERT H, DUBéM P, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy[J]. Nat Genet, 2009,41(12):1345.

[24] DR?GEM?LLER B I, MONZON J G, BHAVSAR A P, et al.Association between SLC16A5 genetic variation and cisplatininduced ototoxic effects in adult patients with testicular cancer[J].JAMA Oncol, 2017, 3(11):1558.

[25] THIESEN S, YIN P, JORGENSEN A L, et al. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatininduced ototoxicity[J]. Pharmacogenet Genomics, 2017, 27(6):213.

[26] YANG J J, LIM J Y, HUANG J, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer[J]. Clin Pharmacol Ther, 2013, 94(2):252.

[27] WG Critical Care, LLC. Cisplatin for injection[EB/OL].(2021-09-01)[2024-04-10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018057s092lbl.pdf.

[28] HULSHOF E C, DEENEN M J, NIJENHUIS M, et al. Dutch pharmacogenetics working group(DPWG)guideline for the genedrug interaction between UGT1A1 and irinotecan[J]. Eur J Hum Genet, 2023, 31(9):982.

[29] ETIENNE-GRIMALDI M C, BOYER J C, THOMAS F, et al.UGT1A1 genotype and irinotecan therapy:general review and implementation in routine practice[J]. Fundam Clin Pharmacol,2015, 29(3):219.

[30] HULSHOF E C, DEENEN M J, GUCHELAAR H J, et al. Pretherapeutic UGT1A1 genotyping to reduce the risk of irinotecaninduced severe toxicity:ready for prime time[J]. Eur J Cancer,2020, 141:9.

[31] DE MAN F M, GOEY A K L, VAN SCHAIK R H N, et al. Individualization of irinotecan treatment:a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics[J].Clin Pharmacokinet, 2018, 57(10):1229.

[32] Pfizer Inc. Camptosar(irinotecan hydrochloride)injection[EB/OL].(2022-01-01)[2024-04-20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020571Orig1s053lbl.pdf.

[33] LEE J W, PUSSEGODA K, RASSEKH S R, et al. Clinical practice recommendations for the management and prevention of cisplatininduced hearing loss using pharmacogenetic markers[J]. Ther Drug Monit, 2016, 38(4):423.

[34]中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组.肺血栓栓塞症诊治与预防指南[J].中华医学杂志, 2018, 98(14):1060.

[35] KONSTANTINIDES S V, MEYER G, BECATTINI C, et al.2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society(ERS)[J]. Eur Heart J, 2020, 41(4):543.

[36] SHEHAB N, SPERLING L S, KEGLER S R, et al. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin[J].Arch Intern Med, 2010, 170(21):1926.

[37] DUFFETT L, CASTELLUCCI L A, FORGIE M A. Pulmonary embolism:update on management and controversies[J]. BMJ,2020, 370:m2177.

[38] JOHNSON J A, CAUDLE K E, GONG L, et al. Clinical pharmacogenetics implementation consortium(CPIC)guideline for pharmacogenetics-guided warfarin dosing:2017 update[J]. Clin Pharmacol Ther, 2012, 102(3):397.

[39] TANG W, SHI Q P, DING F, et al. Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage:a novel systematic review and meta-analysis of 53 studies[J]. Int J Clin Pharmacol Ther, 2017, 55(4):304.

[40] MA C, ZHANG Y X, XU Q, et al. Influence of warfarin doseassociated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin[J]. Int J Hematol, 2012, 96(6):719.

[41] ZHANG J H, CHEN Z J, CHEN C M. Impact of CYP2C9, VKORC1and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients:a systematic review and metaanalysis[J]. Meta Gene, 2016, 9:197.

[42] CALDWELL M D, AWAD T, JOHNSON J A, et al. CYP4F2genetic variant alters required warfarin dose[J]. Blood, 2008,111(8):4106.

[43] Bristol-Myers Squibb Company. Coumadin[EB/OL].(2017-08-01)[2024-04-10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s118lbl.pdf.

[44]中华医学会心血管病学分会,中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013, 52(1):76.

[45] MAGAVERN E F, KASKI J C, TURNER R M, et al. The role of pharmacogenomics in contemporary cardiovascular therapy:a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy[J]. Eur Heart J Cardiovasc Pharmacother, 2022, 8(1):85.

[46] PIRMOHAMED M, BURNSIDE G, ERIKSSON N, et al. A randomized trial of genotype-guided dosing of warfarin[J]. N Engl J Med, 2013, 369(24):2294.

[47] GAO W Q, ZHANG Z J, GUAN Z B, et al. Developing Chinese race-specific warfarin dose prediction algorithms[J]. Int J Clin Pharm, 2023, 45(3):731.

[48] MAR P L, GOPINATHANNAIR R, GENGLER B E, et al. Drug interactions affecting oral anticoagulant use[J]. Circ Arrhythm Electrophysiol, 2022, 15(6):e007956.

[49] SPANGLER M L, SAXENA S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli[J]. Clin Ther, 2010, 32(1):53.

[50] GOLDHABER S Z, AGENO W, CASELLA I B, et al. Safety and effectiveness of dabigatran in routine clinical practice:the RECOVERY DVT/PE study[J]. J Thromb Thrombolysis, 2022,53(2):399.

[51] RAYMOND J, IMBERT L, COUSIN T, et al. Pharmacogenetics of direct oral anticoagulants:a systematic review[J]. J Pers Med,2021, 11(1):37.

[52] PARéG, ERIKSSON N, LEHR T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding[J].Circulation, 2013, 127(13):1404.

[53] JI Q Y, ZHANG C Y, XU Q, et al. The impact of ABCB1 and CES1 polym orphisms on dabigatran pharmacokinetics a n d pharmacodynamics in patients with atrial fibrillation[J]. Br J Clin Pharmacol, 2021, 87(5):2247.

[54] LI G L, LI Q H, ZHANG C J, et al. The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals[J]. Front Genet, 2023, 14:1242711.

[55] HAMADEH I S, KLINKER K P, BORGERT S J, et al. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections[J]. Pharmacogenet Genomics, 2017,27(5):190.

[56] MORIYAMA B, OBENG A O, BARBARINO J, et al. Clinical pharmacogenetics implementation consortium(CPIC)guidelines for CYP2C19 and voriconazole therapy[J]. Clin Pharmacol Ther, 2017, 102(1):45.

[57]泊沙康唑临床应用专家组.泊沙康唑临床应用专家共识(2022版)[J].中华临床感染病杂志, 2022, 15(5):321.

[58]陈欣,林韧.艾沙康唑临床应用专家共识(2023版)[J].临床血液学杂志, 2023, 36(5):295.

[59] LIMPER A H, KNOX K S, SAROSI G A, et al. An official American Thoracic Society statement:treatment of fungal infections in adult pulmonary and critical care patients[J]. Am J Respir Crit Care Med, 2011, 183(1):96.

[60] PATTERSON T F, THOMPSON G R 3rd, DENNING D W, et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the infectious diseases society of America[J]. Clin Infect Dis, 2016, 63(4):e1.

[61] GROLL A H, TOWNSEND R, DESAI A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4[J]. Transpl Infect Dis, 2017, 19(5):10.1111/tid.12751.

[62] Pfizer Inc. VFEND(voriconazole)tablets[EB/OL].(2022-10-18)[2024-4-10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021266s053,021267s063,021630s042lbl.pdf.

[63] MDS. Noxafil(posaconazole)injection for intravenous use[EB/OL].(2022-01-20)[2024-4-10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205053Orig1s013lbl.pdf.

[64] LOPEZ J L, TAYEK J A. Voriconazole-induced hepatitis via simvastatin-and lansoprazole-mediated drug interactions:a case report and review of the literature[J]. Drug Metab Dispos, 2016,44(1):124.

[65] STEFFEL J, COLLINS R, ANTZ M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J].Europace, 2021, 23(10):1612.

[66] GIBSON C M, MEHRAN R, BODE C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J]. N Engl J Med, 2016, 375(25):2423.

[67] SYCHEV D A, BATURINA O A, MIRZAEV K B, et al.CYP2C19*17 may increase the risk of death among patients with an acute coronary syndrome and non-valvular atrial fibrillation who receive clopidogrel and rivaroxaban[J]. Pharmgenomics Pers Med, 2020, 13:29.

[68] EL ROUBY N, LIMA J J, JOHNSON J A. Proton pump inhibitors:from CYP2C19 pharmacogenetics to precision medicine[J].Expert Opin Drug Metab Toxicol, 2018, 14(4):447.

[69] MAFURU M, WU S L, MAYALA H, et al. Analysis of combined effect of CYP2C19 genetic polymorphism and proton pump inhibitors coadministration on trough concentration of voriconazole[J]. Pharmgenomics Pers Med, 2021, 14:1379.

[70]连玉菲,刘洪涛,任炳楠,等.伏立康唑与奥美拉唑联合应用致伏立康唑超快代谢型患者血药浓度增高的分析[J].中国药物警戒,2020, 17(8):496.

[71]中国医师协会骨科医师分会骨循环与骨坏死专业委员会,中华医学会骨科分会骨显微修复学组,国际骨循环学会中国区.中国成人股骨头坏死临床诊疗指南(2020)[J].中华骨科杂志, 2020,40(20):1365.

[72]张聪敏,任凯迪,张绮雯,等.激素性股骨头坏死易感基因的研究进展[J].中国药学杂志, 2022, 57(2):85.

[73] SAKAEDA T, NAKAMURA T, OKUMURA K. MDR1 genotyperelated pharmacokinetics and pharmacodynamics[J]. Biol Pharm Bull, 2002, 25(11):1391.

[74] SUN W, LI Z R, SHI Z C, et al. Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms[J]. Eur J Orthop Surg Traumatol, 2014, 24(4):525.

[75] YANG J, JING M, YANG X G. Association between genetic polymorphisms and osteonecrosis in steroid treatment populations:a detailed stratified and dose-response meta-analysis[J]. Biosci Rep, 2019, 39(5):BSR20190024.

[76]杨晶,张爱玲,鲁憬莉,等. ABCB1基因多态性与糖皮质激素性股骨头坏死相关性的Meta分析[J].中国医院药学杂志, 2016,36(9):732.

[77] Pfizer Inc. PAXLOVID(Nirmatrelvir tablets; Ritonavir tablets),co-packaged for oral use[EB/OL].(2023-04-25)[2024-04-20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf.

[78] LIU P, FOSTER G, GANDELMAN K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects[J]. Antimicrob Agents Chemother,2007, 51(10):3617.

[79] WANG P L, XING H, ZHANG X J, et al. Complexity interactions between nirmatrelvir/ritonavir and voriconazole in patients with coronavirus disease 2019[J]. Clin Infect Dis, 2023, 76(12):2209.

[80] HERRANZ BAYO E, MERCHANTE ANDREU M, HUARTE LACUNZA R, et al. Paradoxical interaction between nirmatrelvir/ritonavir and voriconazole in a patient with COVID-19[J]. Farm Hosp, 2023, 47(2):93.

[81] JIA S J, GAO K Q, HUANG P H, et al. Interactive effects of glucocorticoids and cytochrome P450 polymorphisms on the plasma trough concentrations of voriconazole[J]. Front Pharmacol, 2021, 12:666296.

[82] LI M X, ZHU L Q, CHEN L, et al. Assessment of drug-drug interactions between voriconazole and glucocorticoids[J]. J Chemother, 2018, 30(5):296.

[83] CHEN Y P, FERGUSON S S, NEGISHI M, et al. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter[J]. Mol Pharmacol,2003, 64(2):316.

[84] DOLTON M J, RAY J E, CHEN S C, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring[J].Antimicrob Agents Chemother, 2012, 56(9):4793.